9 November 2026
Thalia Therapeutics plc
("Thalia" or the "Company")
Clinical Trial Agreement signed for miRisten
Agreement with City of Hope supports completion of Phase 1 trial in Acute Myeloid Leukaemia
Topline readout targeted for H1 2027, with interim data expected Q4 2026
Thalia Therapeutics plc (AIM: THAT), a clinical-stage biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease, announces that its wholly-owned subsidiary Sanmirna Therapeutics Inc. (“Sanmirna”) has entered into a Clinical Trial Agreement (“CTA”) with City of Hope in the United States for the ongoing Phase 1 clinical trial of miRisten (THAT-001).
The CTA formalises arrangements regarding the completion of the Phase 1 study, including access to trial results and trial-related information, along with confirmation of the budget, which is in line with the use of proceeds announced on 24 June 2026.
Thalia completed the acquisition of Sanmirna in July 2026, adding miRisten to its development portfolio. Sanmirna holds an exclusive licence from City of Hope, one of the world's leading cancer research and treatment centres, for intellectual property covering miRisten and its uses. The associated £2.75 million fundraise included funding to support completion of the Phase 1 study. Following the acquisition, City of Hope has a 10.6 per cent interest in Thalia.
miRisten is an anti-microRNA-126 therapeutic being evaluated in a Phase 1 dose-escalation clinical trial at City of Hope in patients with relapsed or refractory Acute Myeloid Leukaemia (“AML”). The ongoing study is designed to assess the safety and tolerability of miRisten and explore initial signs of efficacy. An interim readout is expected in the last quarter of 2026, with topline data targeted for the first half of 2027.
Related Party Transaction
As City of Hope is a substantial shareholder in the Company, entering into the CTA is deemed a related party transaction under the AIM Rules. The directors of the Company consider, having consulted with the Company's nominated adviser, SP Angel Corporate Finance LLP, that the terms of the transaction are fair and reasonable insofar as its shareholders are concerned.
Dr David Solomon, Chief Executive Officer of Thalia, commented:
“Completing the Clinical Trial Agreement is an important step in progressing miRisten with City of Hope. Our focus is on supporting completion of the ongoing Phase 1 study and evaluating the resulting data to determine the programme’s next clinical and regulatory steps.
“AML remains an area of significant unmet medical need, particularly for patients whose disease has relapsed or has not responded to existing treatments. We look forward to updating shareholders on the interim and topline results and sharing future plans.”
– Ends –
For further information please contact:
Thalia Therapeutics plc Dr David H Solomon, Chief Executive Officer | Via Thalia Investor Hub |
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | Tel: +44 (0)20 3470 0470 |
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker/Guy McDougall | Tel: +44 (0)20 3657 0050 |
Northstar Communications Limited Investor relations and Communications Sarah Hollins Cohesion Bureau Investor relations and Communications Mary-Ann Chang | Tel: +44 (0)20 7183 2463 Tel: +44 (0)7483 284853 |
About Thalia Therapeutics plc
Thalia Therapeutics is a clinical-stage biotechnology company developing innovative RNA-based therapeutics and delivery technologies across oncology and cardiovascular disease. With a growing, differentiated pipeline, de-risked by validated therapeutic targets, we aim to treat disease at its source by silencing or modifying the genes that cause or contribute to it.
Our clinical-stage programme miRisten (THAT-001) is a microRNA therapeutic in development for Acute Myeloid Leukaemia (AML). Alongside this, our preclinical bispecific siRNA (THAT-002) is being developed as a potential long-acting treatment for atherosclerotic cardiovascular disease by addressing two independent drivers of cardiovascular risk. Our proprietary delivery technology, Nuvec® (THAT-003), offers the potential to overcome the fundamental challenges of RNA delivery, enabling targeted, scalable RNA therapeutics.
For further information visit www.thaliatx.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.